Relmada Therapeutics (RLMD)

Relmada Therapeutics (RLMD) – FDA

Sep 20, 2023 08:31 AM Relmada Therapeutics (RLMD) Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
Dec 7, 2022 04:07 PM Relmada Therapeutics (RLMD) Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder Did Not Achieve Primary Endpoint
Oct 13, 2022 07:04 AM
Aug 9, 2022 08:31 AM
Apr 29, 2022 08:31 AM
Feb 23, 2022 06:32 AM
Dec 22, 2021 09:02 AM
Oct 4, 2021 08:32 AM
Sep 13, 2021 06:06 PM
Jul 27, 2021 11:37 AM
Jul 27, 2021 07:35 AM
Apr 1, 2021 08:07 AM
Dec 7, 2020 08:40 AM
May 27, 2020 08:08 AM
Oct 15, 2019 08:06 AM
Sep 18, 2018 08:09 AM
Jun 27, 2018 08:10 AM